Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: polyarticular arthritis

Reactive Arthritis: Chronic or Self-Limiting?

Michael J. Cammarata, MD  |  June 8, 2025

Reactive arthritis has proved to be a diagnostic & therapeutic challenge due to its diverse presentations.

Filed under:Axial SpondyloarthritisConditions Tagged with:biologic DMARDsdisease managementextra-articular manifestationsGlucocorticoidsHLA-B27infectious etiologymusculoskeletal manifestationsNSAIDsReactive arthritisspondyloarthritissulfasalazine

The Heterogeneity of Psoriatic Arthritis

David S. Pisetsky, MD, PhD  |  November 21, 2023

SAN DIEGO—Differences between psoriatic arthritis and rheumatoid arthritis highlight the need for the development of imaging modalities, laboratory tests and other biomarkers that are explored and validated specifically for PsA to advance the goal of personalized or precision medicine. In this article, expert David S. Pisetsky, MD, PhD, explores the top research in psoriatic arthritis presented at ACR Convergence 2023.

Filed under:ACR ConvergenceConditionsMeeting ReportsPsoriatic Arthritis Tagged with:ACR Convergence 2023ACR Convergence 2023 PsAPsA Resource Center

FDA Approves New Biosimilar for Adult & Pediatric Arthritis

Michele B. Kaufman, PharmD, BCGP  |  November 6, 2023

This year, tocilizumab biosimilars have been approved to treat adult and pediatric patients with rheumatic disease, including rheumatoid arthritis, juvenile idiopathic arthritis and more, in both Europe and the U.S.

Filed under:Biologics/DMARDsDrug UpdatesPediatric ConditionsRheumatoid Arthritis Tagged with:BiosimilarstocilizumabU.S. Food and Drug Administration (FDA)

Lost and found

A Look Back at the First Use of Cortisone in Rheumatoid Arthritis

Ruth Jessen Hickman, MD  |  January 17, 2023

In 1949, the first description of patients with rheumatoid arthritis (RA) given cortisone sent shockwaves through the medical community, quickly capturing the public imagination as well. The paradigm-shifting report paved the way for the use of cortisone and related drugs in RA and many other medical conditions.1 The following is a discussion of some of…

Filed under:ConditionsRheumatoid Arthritis Tagged with:cortisoneLost & Found

Baricitinib Promising for Juvenile Idiopathic Arthritis

Michele B. Kaufman, PharmD, BCGP  |  July 19, 2022

In a study from Ramanan et al., baricitinib proved safe and effective for reducing the time to flare and frequency of flare in patients aged 2–18 years with juvenile idiopathic arthritis.

Filed under:ConditionsDrug UpdatesEULAR/OtherMeeting ReportsPediatric Conditions Tagged with:baricitinibEULARflareJIAjuvenile idiopathic arthritis (JIA)PediatricPediatric Rheumatology

Case Report: Rheumatoid Arthritis Complicated by Large Granular Lymphocytic Leukemia

Nam D. Nguyen, DO (Maj., USAF, MC), Erica Hill, DO (Lt. Col., USAF, MC), & Jay Higgs, MD (Col. [ret], USAF, MC)  |  November 14, 2021

Large granular lymphocytic (LGL) leukemia is a rare, chronic, lymphoproliferative disorder of cytotoxic T cell or natural killer cell lineage with an annual incidence of 0.72 cases per 1 million people in the U.S.1 The most common sub­type of LGL leukemia, T-LGL leukemia, follows an indolent disease course and accounts for approximately 85% of cases….

Filed under:ConditionsRheumatoid Arthritis Tagged with:large granular lymphocyte leukemiavertebral fracture

Outcome Assessments: Measuring Global Disease Activity in Patients with Psoriatic Arthritis

Jason Liebowitz, MD, FACR  |  June 23, 2021

Laura Coates, MBChB, MRCP, PhD, described & compared the intricacies of different outcome measures, as well as implications for clinical practice & trials, for patients with psoriatic arthritis.

Filed under:ConditionsEULAR/OtherMeeting ReportsPsoriatic Arthritis Tagged with:EULARoutcomeOutcome measuresPsoriatic Arthritis

FDA Approves Golimumab for Patients with pJIA & Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP  |  October 21, 2020

The FDA has approved golimumab for the treatment of pediatric patients with active polyarticular juvenile idiopathic arthritis or active psoriatic arthritis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPediatric Conditions Tagged with:FDA approvalGolimumabPediatricpolyarticular juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritis (JIA)Psoriatic ArthritisU.S. Food and Drug Administration (FDA)

FDA Approves Tofacitinib for Young Patients with Active Polyarticular JIA

Michele B. Kaufman, PharmD, BCGP  |  October 9, 2020

Tofacitinib is now FDA approved to treat patients 2 years and older with active, polyarticular juvenile idiopathic arthritis.

Filed under:Drug Updates Tagged with:FDApolyarticular juvenile idiopathic arthritis (JIA)TofacitinibU.S. Food and Drug Administration (FDA)

More Than Skin Deep: Insights into Clinical Challenges in Psoriatic Arthritis

Jason Liebowitz, MD, FACR  |  October 7, 2019

Accurately classifying patients with psoriatic arthritis (PsA) can be difficult, especially patients with monoarticular/oligoarticular and polyarticular forms of PsA. A session at the 2019 European Congress of Rheumatology provided insight into the assessment and treatment of PsA subtypes…

Filed under:ConditionsEULAR/OtherMeeting ReportsPsoriatic Arthritis Tagged with:EULARPsoriatic Arthritisskin

  • 1
  • 2
  • 3
  • …
  • 14
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences